PDS-2™ System
Plaque regression in Homozygous Familial Hypercholesterolemia (HoFH)
ApprovedActive
Key Facts
Indication
Plaque regression in Homozygous Familial Hypercholesterolemia (HoFH)
Phase
Approved
Status
Active
Company
About HDL Therapeutics
HDL Therapeutics, founded in 2015 and based in Houston, Texas, is a private biotech company targeting cardiovascular and metabolic diseases. The company's core asset is the PDS-2™ System, which is described as the only FDA-approved therapy designed to regress coronary plaques in patients with Homozygous Familial Hypercholesterolemia (HoFH) by leveraging HDL. This positions the company with a commercial-stage product for a severe, rare disease while potentially pursuing broader atherosclerosis applications. The leadership team brings decades of combined experience from the pharmaceutical, biotechnology, and medical device industries.
View full company profile